Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5EN79)

• Drug Name: Levamisole Drug Info
• Synonyms: Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 26879
  ChEBI ID: CHEMBL1454
  CAS Number: CAS 14769-73-4
  TTD Drug ID: D0CF2Q
  INTEDE Drug ID: DR2400

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	1.94	1.05e-2	34/36 (94.44%)	PCNA;POLE2;FEN1;...
Fanconi anemia pathway	1.82	3.66e-2	36/54 (66.67%)	BRIP1;BRCA1;FANCL;...
Homologous recombination	1.76	4.18e-2	35/41 (85.37%)	BRIP1;BRCA1;BARD1;...
Spliceosome	1.73	3.79e-2	101/150 (67.33%)	LSM5;HSPA1A;HNRNPA1;...
Antigen processing and presentation	-1.73	3.94e-2	60/78 (76.92%)	HSPA1L;LGMN;HLA-A;...
Alanine, aspartate and glutamate metabolism	-1.73	4.03e-2	27/37 (72.97%)	DDO;GOT1;ASPA;...
Butanoate metabolism	-1.79	2.53e-2	23/28 (82.14%)	HMGCS2;AACS;ACADS;...
Other glycan degradation	-1.79	2.49e-2	13/18 (72.22%)	ENGASE;GLB1;MAN2B1;...
Type I diabetes mellitus	-1.82	2.12e-2	38/43 (88.37%)	HLA-A;HLA-DQB1;HLA-E;...
Gap junction	-1.85	2.01e-2	72/88 (81.82%)	TJP1;PDGFA;PRKCA;...
Viral protein interaction with cytokine and cytokine re...	-1.87	2.09e-2	84/100 (84%)	CXCL1;CCL25;TNFRSF1A;...
Intestinal immune network for IgA production	-1.87	2.44e-2	38/48 (79.17%)	HLA-DQB1;CCR10;CD40;...
Allograft rejection	-1.87	2.93e-2	32/38 (84.21%)	HLA-A;HLA-DQB1;HLA-E;...
IL-17 signaling pathway	-1.91	2.20e-2	84/94 (89.36%)	CCL17;MAPK14;MAPK6;...
Graft-versus-host disease	-1.96	1.95e-2	32/42 (76.19%)	HLA-A;HLA-DQB1;HLA-E;...
Mitophagy	-1.99	2.20e-2	56/68 (82.35%)	MFN2;BCL2L13;TAX1BP1;...
Steroid biosynthesis	-2.08	1.46e-2	19/20 (95%)	SOAT2;SOAT1;HSD17B7;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	15uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼